STRO vs PLUR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
STRO Captures Institutional Edge (3โ1 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Sutro Biopharma, Inc. (STRO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while PLUR counters with relative strength in Valuation. Fundamentally, STRO trades at 10.0x Forward P/E with -254.7% operating margin (-6.1% YoY revenue) versus PLUR at 3.6x Forward P/E and -2454.5% operating margin (-15.8% YoY). In options structure, STRO sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against PLUR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | STRO | PLUR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $163.0M | $15.1M | Larger Scale | STRO |
| Trailing P/E Ratio Valuation | 10.0x | 3.6x | Lower Multiple | PLUR |
| Forward P/E Ratio Valuation | 10.0x | 3.6x | Lower Multiple | PLUR |
| Revenue Growth (YoY) Growth | -6.1% | -15.8% | Higher Growth | STRO |
| Operating Margin (TTM) Profitability | -254.7% | -2454.5% | Higher Margin | STRO |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -1810.0% | -1022.0% | Higher ROE | PLUR |
| 52-Week Range Position Momentum | 19% ($1โ$44) | 2% ($1โ$5) | Stronger Trend | STRO |
| Beta / 30D Volatility Risk Regime | 1.65ฮฒ ยท 80% Vol | 0.80ฮฒ ยท 102% Vol | Lower Realized Risk | STRO |
| Unified Institutional Score Composite Signal | 45.1 / 100 (HOLD) | 28.8 / 100 (SELL) | Higher Composite | STRO |